The AP1AR Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited heterogeneous cell population derived from the A-549 human lung adenocarcinoma cell line, with targeted disruption of the AP1AR gene. Loss of AP1AR function allows researchers to dissect the role of this adaptor protein in intracellular trafficking. The polyclonal nature captures a spectrum of knockout genotypes, providing a robust loss-of-function model without clonal isolation, ideal for initial screens and pooled population studies.
A-549 cells, originating from a human lung carcinoma, are widely utilized as a model of type II alveolar epithelial cells. They exhibit active endocytic and secretory pathways and are extensively characterized in cancer research. This host line offers a relevant cellular context for examining how AP-1 complex-mediated trafficking influences adenocarcinoma cell behavior.
AP1AR, also termed ??-synergin, directly binds the ??-adaptin (AP1G1) subunit of the AP-1 complex and clathrin at the trans-Golgi network and endosomal membranes. It facilitates clathrin-mediated sorting of mannose-6-phosphate receptors (CI-MPR and CD-MPR), which target lysosomal hydrolases. Upstream, ARF GTPases promote AP-1 membrane association. Downstream cargos include LAMP1, LAMP2, cathepsins, and TGN46. Through these interactions, AP1AR regulates retrograde and anterograde trafficking between the TGN and endosomes, essential for lysosomal biogenesis and endosomal maturation.
In the A-549 background, AP1AR knockout disrupts normal cargo sorting, leading to aberrant lysosomal enzyme delivery and receptor mislocalization. This can manifest as altered degradation kinetics, changes in surface receptor levels, and compromised endosomal acidification. Given the involvement of endolysosomal pathways in cancer cell survival and metastasis, this model is valuable for investigating how trafficking defects contribute to lung adenocarcinoma pathology.
Typical experimental approaches include immunoblotting and immunofluorescence for AP-1 subunits (??, ??1, ??1, ??1), CI-MPR, LAMP1, and TGN46; flow cytometry for CD-MPR surface expression; and cathepsin activity assays. Functional studies such as wound healing, transwell invasion, and chemosensitivity testing can link AP1AR loss to phenotypic changes. Transcriptomic profiling via RNA-seq further reveals alterations in endolysosomal gene networks. This product is suited for both mechanistic and translational studies in membrane trafficking and lung cancer. For additional technical information, please contact Ascent Research.
